Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Filing tables
Filing exhibits
Related press release
DAWN similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1)
Registration Statements (Form S-8 No. 333-256521, 333-263343, 333-268071, 333-269727 and 333-276372) pertaining to the 2021 Equity Incentive Plan, 2021 Employee Stock Purchase Plan and 2022 Equity Inducement Plan of Day One Biopharmaceuticals, Inc., and
(2)
Registration Statements (Form S-3 No. 333-265346 and 333-274521) of Day One Biopharmaceuticals, Inc.
of our report dated March 6, 2023, with respect to the consolidated financial statements of Day One Biopharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2023.
/S/ Ernst & Young LLP
San Mateo, California
February 26, 2024